Basilea Pharmaceutica receives a $900,000 grant from CARB-X to develop novel antibiotics targeting LptA in Gram-negative bacteria.
Basilea Pharmaceutica secures a $900,000 grant from CARB-X, a global non-profit, to develop a novel class of antibiotics targeting LptA in Gram-negative bacteria. The program aims to combat antibiotic-resistant strains such as E. coli and K. pneumoniae. Funding comes in part from the US Department of Health and Human Services, Wellcome, and Germany's Federal Ministry of Education and Research.
April 09, 2024
4 Articles